Zhou Liu-Qing, Shen Jin-Xiong, Zhou Tao, Li Chun-Li, Hu Yao, Xiao Hong-Jun
Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Otorhinolaryngology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China.
Front Genet. 2022 Aug 9;13:953739. doi: 10.3389/fgene.2022.953739. eCollection 2022.
-Catenin has been recently identified as a promising novel therapeutic target and prognostic marker in different types of cancer. Here, we conduct a meta-analysis to better clarify the correlation between -Catenin expression and survival outcomes in nasopharyngeal carcinoma (NPC) patients. Following the Preferred Reporting Items or Systematic Reviews Meta Analyses (PRISMA) 2020 guidelines, the PubMed, Embase, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases were systematically searched for relevant studies to explore the prognostic significance of -Catenin in NPC. Pooled hazards ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the association of -Catenin expression with survival outcomes in NPC patients. Odd ratios (ORs) and 95% CIs for clinicopathological characteristics were also statistically analyzed. Eight studies involving 1,179 patients with NPC were ultimately included in the meta-analysis. Pooled analysis indicated that elevated -Catenin expression was significantly associated with poor OS (HR = 2.45, 95% CIs: 1.45-4.16, = 0.001) and poor DFS/PFS (HR 1.79, 95% CIs: 1.29-2.49, = 0.000). Furthermore, -cadherin was signifcantly associated with higher TMN stages (OR = 5.10, 95% CIs 2.93-8.86, = 0.000), clinical stages (OR = 5.10, 95% CIs 2.93-8.86, = 0.000) and lymph node metastasis (LNM) (OR = 5.01, 95% CIs 2.40-10.44, = 0.000). This study demonstrated that for NPC, patients with elevated -Catenin expression are more likely to have poor survival.
最近,β-连环蛋白已被确定为不同类型癌症中有前景的新型治疗靶点和预后标志物。在此,我们进行一项荟萃分析,以更好地阐明β-连环蛋白表达与鼻咽癌(NPC)患者生存结果之间的相关性。按照《系统评价和荟萃分析优先报告项目》(PRISMA)2020指南,我们系统检索了PubMed、Embase、Web of Science、Cochrane图书馆、中国知网(CNKI)和万方数据库中的相关研究,以探讨β-连环蛋白在NPC中的预后意义。采用合并风险比(HRs)和95%置信区间(CIs)来估计β-连环蛋白表达与NPC患者生存结果之间的关联。还对临床病理特征的比值比(ORs)和95% CIs进行了统计学分析。最终,八项涉及1179例NPC患者的研究被纳入荟萃分析。汇总分析表明,β-连环蛋白表达升高与总生存期(OS)较差(HR = 2.45,95% CIs:1.45 - 4.16,P = 0.001)和无病生存期/进展生存期(DFS/PFS)较差(HR 1.79,95% CIs:1.29 - 2.49,P = 0.000)显著相关。此外,β-连环蛋白与更高的TMN分期(OR = 5.10,95% CIs 2.93 - 8.86,P = 0.000)、临床分期(OR = 5.10,95% CIs 2.93 - 8.86,P = 0.000)和淋巴结转移(LNM)(OR = 5.01,95% CIs 2.40 - 10.44,P = 0.000)显著相关。本研究表明,对于NPC患者,β-连环蛋白表达升高的患者更有可能生存较差。